nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2B6—Sorafenib—thyroid cancer	0.141	0.189	CbGbCtD
Nevirapine—CYP3A5—Sorafenib—thyroid cancer	0.111	0.149	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—thyroid cancer	0.0855	0.115	CbGbCtD
Nevirapine—CYP1A2—Sorafenib—thyroid cancer	0.0827	0.111	CbGbCtD
Nevirapine—CYP2C9—Sorafenib—thyroid cancer	0.0745	0.0999	CbGbCtD
Nevirapine—CYP3A4—Vandetanib—thyroid cancer	0.0718	0.0964	CbGbCtD
Nevirapine—CYP2D6—Sorafenib—thyroid cancer	0.0681	0.0913	CbGbCtD
Nevirapine—CYP3A4—Sorafenib—thyroid cancer	0.0433	0.0581	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—thyroid cancer	0.0413	0.0554	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—thyroid cancer	0.0263	0.0352	CbGbCtD
Nevirapine—Rhabdomyolysis—Sorafenib—thyroid cancer	0.00363	0.0143	CcSEcCtD
Nevirapine—Dermatitis bullous—Vandetanib—thyroid cancer	0.00361	0.0142	CcSEcCtD
Nevirapine—Bone disorder—Sorafenib—thyroid cancer	0.00355	0.014	CcSEcCtD
Nevirapine—Drug interaction—Sorafenib—thyroid cancer	0.00346	0.0136	CcSEcCtD
Nevirapine—Blood pressure increased—Sorafenib—thyroid cancer	0.00321	0.0126	CcSEcCtD
Nevirapine—Rash papular—Epirubicin—thyroid cancer	0.00318	0.0125	CcSEcCtD
Nevirapine—Skin exfoliation—Sorafenib—thyroid cancer	0.00306	0.012	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00305	0.012	CcSEcCtD
Nevirapine—Bullous eruption—Epirubicin—thyroid cancer	0.003	0.0118	CcSEcCtD
Nevirapine—Rash papular—Doxorubicin—thyroid cancer	0.00295	0.0116	CcSEcCtD
Nevirapine—Opportunistic infection—Epirubicin—thyroid cancer	0.00295	0.0116	CcSEcCtD
Nevirapine—Pancreatitis—Vandetanib—thyroid cancer	0.00293	0.0115	CcSEcCtD
Nevirapine—Mouth ulceration—Sorafenib—thyroid cancer	0.0029	0.0114	CcSEcCtD
Nevirapine—Neutropenia—Vandetanib—thyroid cancer	0.00279	0.011	CcSEcCtD
Nevirapine—Bullous eruption—Doxorubicin—thyroid cancer	0.00278	0.0109	CcSEcCtD
Nevirapine—Erythema nodosum—Epirubicin—thyroid cancer	0.00274	0.0108	CcSEcCtD
Nevirapine—Opportunistic infection—Doxorubicin—thyroid cancer	0.00273	0.0107	CcSEcCtD
Nevirapine—Hyperglycaemia—Vandetanib—thyroid cancer	0.00269	0.0106	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00264	0.0104	CcSEcCtD
Nevirapine—Renal failure—Vandetanib—thyroid cancer	0.00262	0.0103	CcSEcCtD
Nevirapine—Hepatic failure—Sorafenib—thyroid cancer	0.00259	0.0102	CcSEcCtD
Nevirapine—Conjunctivitis—Vandetanib—thyroid cancer	0.00259	0.0102	CcSEcCtD
Nevirapine—Ulcerative stomatitis—Epirubicin—thyroid cancer	0.00257	0.0101	CcSEcCtD
Nevirapine—Erythema nodosum—Doxorubicin—thyroid cancer	0.00254	0.00998	CcSEcCtD
Nevirapine—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00252	0.00989	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.00247	0.00971	CcSEcCtD
Nevirapine—Ulcerative stomatitis—Doxorubicin—thyroid cancer	0.00238	0.00934	CcSEcCtD
Nevirapine—Erythema multiforme—Vandetanib—thyroid cancer	0.00226	0.00888	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.0021	0.00825	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.0021	0.00825	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00206	0.00808	CcSEcCtD
Nevirapine—Pancreatitis—Sorafenib—thyroid cancer	0.00197	0.00776	CcSEcCtD
Nevirapine—Transaminases increased—Epirubicin—thyroid cancer	0.00195	0.00766	CcSEcCtD
Nevirapine—Neutropenia—Sorafenib—thyroid cancer	0.00188	0.0074	CcSEcCtD
Nevirapine—Transaminases increased—Doxorubicin—thyroid cancer	0.0018	0.00709	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00178	0.007	CcSEcCtD
Nevirapine—Arthralgia—Vandetanib—thyroid cancer	0.00177	0.00696	CcSEcCtD
Nevirapine—Renal failure—Sorafenib—thyroid cancer	0.00177	0.00694	CcSEcCtD
Nevirapine—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00176	0.00692	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00176	0.00691	CcSEcCtD
Nevirapine—Jaundice—Sorafenib—thyroid cancer	0.00175	0.00688	CcSEcCtD
Nevirapine—Hepatobiliary disease—Sorafenib—thyroid cancer	0.0017	0.00667	CcSEcCtD
Nevirapine—Oedema—Vandetanib—thyroid cancer	0.0017	0.00667	CcSEcCtD
Nevirapine—Nervous system disorder—Vandetanib—thyroid cancer	0.00167	0.00654	CcSEcCtD
Nevirapine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00166	0.00653	CcSEcCtD
Nevirapine—Skin disorder—Vandetanib—thyroid cancer	0.00165	0.00648	CcSEcCtD
Nevirapine—Blister—Epirubicin—thyroid cancer	0.00165	0.00647	CcSEcCtD
Nevirapine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00158	0.00623	CcSEcCtD
Nevirapine—Rash erythematous—Epirubicin—thyroid cancer	0.00155	0.00609	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00155	0.00608	CcSEcCtD
Nevirapine—Paraesthesia—Vandetanib—thyroid cancer	0.00152	0.00599	CcSEcCtD
Nevirapine—Erythema multiforme—Sorafenib—thyroid cancer	0.00152	0.00599	CcSEcCtD
Nevirapine—Blister—Doxorubicin—thyroid cancer	0.00152	0.00599	CcSEcCtD
Nevirapine—Necrosis—Epirubicin—thyroid cancer	0.00151	0.00594	CcSEcCtD
Nevirapine—Decreased appetite—Vandetanib—thyroid cancer	0.00148	0.0058	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00147	0.00576	CcSEcCtD
Nevirapine—Fatigue—Vandetanib—thyroid cancer	0.00146	0.00575	CcSEcCtD
Nevirapine—Immune system disorder—Sorafenib—thyroid cancer	0.00146	0.00572	CcSEcCtD
Nevirapine—Pain—Vandetanib—thyroid cancer	0.00145	0.00571	CcSEcCtD
Nevirapine—Rash erythematous—Doxorubicin—thyroid cancer	0.00143	0.00563	CcSEcCtD
Nevirapine—Liver injury—Epirubicin—thyroid cancer	0.00141	0.00554	CcSEcCtD
Nevirapine—Erythema—Sorafenib—thyroid cancer	0.0014	0.00552	CcSEcCtD
Nevirapine—Necrosis—Doxorubicin—thyroid cancer	0.0014	0.0055	CcSEcCtD
Nevirapine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00139	0.00546	CcSEcCtD
Nevirapine—Body temperature increased—Vandetanib—thyroid cancer	0.00134	0.00527	CcSEcCtD
Nevirapine—Abdominal pain—Vandetanib—thyroid cancer	0.00134	0.00527	CcSEcCtD
Nevirapine—Bone disorder—Epirubicin—thyroid cancer	0.00131	0.00516	CcSEcCtD
Nevirapine—Liver injury—Doxorubicin—thyroid cancer	0.0013	0.00513	CcSEcCtD
Nevirapine—Anaemia—Sorafenib—thyroid cancer	0.0013	0.0051	CcSEcCtD
Nevirapine—Angioedema—Sorafenib—thyroid cancer	0.00128	0.00504	CcSEcCtD
Nevirapine—Ulcer—Epirubicin—thyroid cancer	0.00125	0.00493	CcSEcCtD
Nevirapine—Inflammation—Epirubicin—thyroid cancer	0.00122	0.00481	CcSEcCtD
Nevirapine—Asthenia—Vandetanib—thyroid cancer	0.00122	0.00479	CcSEcCtD
Nevirapine—Bone disorder—Doxorubicin—thyroid cancer	0.00122	0.00478	CcSEcCtD
Nevirapine—Pruritus—Vandetanib—thyroid cancer	0.0012	0.00472	CcSEcCtD
Nevirapine—Myalgia—Sorafenib—thyroid cancer	0.00119	0.0047	CcSEcCtD
Nevirapine—Arthralgia—Sorafenib—thyroid cancer	0.00119	0.0047	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00119	0.00466	CcSEcCtD
Nevirapine—Hepatocellular injury—Epirubicin—thyroid cancer	0.00119	0.00466	CcSEcCtD
Nevirapine—Diarrhoea—Vandetanib—thyroid cancer	0.00116	0.00457	CcSEcCtD
Nevirapine—Ulcer—Doxorubicin—thyroid cancer	0.00116	0.00456	CcSEcCtD
Nevirapine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00115	0.0045	CcSEcCtD
Nevirapine—Skin exfoliation—Epirubicin—thyroid cancer	0.00113	0.00445	CcSEcCtD
Nevirapine—Inflammation—Doxorubicin—thyroid cancer	0.00113	0.00445	CcSEcCtD
Nevirapine—Nervous system disorder—Sorafenib—thyroid cancer	0.00112	0.00441	CcSEcCtD
Nevirapine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00112	0.00441	CcSEcCtD
Nevirapine—Skin disorder—Sorafenib—thyroid cancer	0.00111	0.00437	CcSEcCtD
Nevirapine—Hepatocellular injury—Doxorubicin—thyroid cancer	0.0011	0.00431	CcSEcCtD
Nevirapine—Anorexia—Sorafenib—thyroid cancer	0.00109	0.00429	CcSEcCtD
Nevirapine—Vomiting—Vandetanib—thyroid cancer	0.00108	0.00424	CcSEcCtD
Nevirapine—Rash maculo-papular—Epirubicin—thyroid cancer	0.00108	0.00424	CcSEcCtD
Nevirapine—Mouth ulceration—Epirubicin—thyroid cancer	0.00107	0.00422	CcSEcCtD
Nevirapine—Rash—Vandetanib—thyroid cancer	0.00107	0.00421	CcSEcCtD
Nevirapine—Dermatitis—Vandetanib—thyroid cancer	0.00107	0.0042	CcSEcCtD
Nevirapine—Headache—Vandetanib—thyroid cancer	0.00106	0.00418	CcSEcCtD
Nevirapine—Skin exfoliation—Doxorubicin—thyroid cancer	0.00105	0.00412	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00104	0.0041	CcSEcCtD
Nevirapine—Lymphadenopathy—Epirubicin—thyroid cancer	0.00101	0.00397	CcSEcCtD
Nevirapine—Nausea—Vandetanib—thyroid cancer	0.00101	0.00396	CcSEcCtD
Nevirapine—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000998	0.00392	CcSEcCtD
Nevirapine—Decreased appetite—Sorafenib—thyroid cancer	0.000996	0.00391	CcSEcCtD
Nevirapine—Mouth ulceration—Doxorubicin—thyroid cancer	0.000992	0.0039	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000989	0.00389	CcSEcCtD
Nevirapine—Fatigue—Sorafenib—thyroid cancer	0.000987	0.00388	CcSEcCtD
Nevirapine—Pain—Sorafenib—thyroid cancer	0.000979	0.00385	CcSEcCtD
Nevirapine—Hepatic failure—Epirubicin—thyroid cancer	0.000958	0.00377	CcSEcCtD
Nevirapine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000937	0.00368	CcSEcCtD
Nevirapine—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000934	0.00367	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000913	0.00359	CcSEcCtD
Nevirapine—Urticaria—Sorafenib—thyroid cancer	0.00091	0.00358	CcSEcCtD
Nevirapine—Body temperature increased—Sorafenib—thyroid cancer	0.000905	0.00356	CcSEcCtD
Nevirapine—Abdominal pain—Sorafenib—thyroid cancer	0.000905	0.00356	CcSEcCtD
Nevirapine—Dermatitis bullous—Epirubicin—thyroid cancer	0.000901	0.00354	CcSEcCtD
Nevirapine—Hepatic failure—Doxorubicin—thyroid cancer	0.000887	0.00348	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000844	0.00332	CcSEcCtD
Nevirapine—Hypersensitivity—Sorafenib—thyroid cancer	0.000844	0.00332	CcSEcCtD
Nevirapine—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000834	0.00328	CcSEcCtD
Nevirapine—Face oedema—Epirubicin—thyroid cancer	0.000831	0.00327	CcSEcCtD
Nevirapine—Asthenia—Sorafenib—thyroid cancer	0.000822	0.00323	CcSEcCtD
Nevirapine—Pruritus—Sorafenib—thyroid cancer	0.00081	0.00318	CcSEcCtD
Nevirapine—Liver function test abnormal—Epirubicin—thyroid cancer	0.000795	0.00312	CcSEcCtD
Nevirapine—Diarrhoea—Sorafenib—thyroid cancer	0.000784	0.00308	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000775	0.00305	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000775	0.00305	CcSEcCtD
Nevirapine—Face oedema—Doxorubicin—thyroid cancer	0.000769	0.00302	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00076	0.00299	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—thyroid cancer	0.000737	0.0029	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000736	0.00289	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—thyroid cancer	0.00073	0.00287	CcSEcCtD
Nevirapine—Vomiting—Sorafenib—thyroid cancer	0.000728	0.00286	CcSEcCtD
Nevirapine—Rash—Sorafenib—thyroid cancer	0.000722	0.00284	CcSEcCtD
Nevirapine—Dermatitis—Sorafenib—thyroid cancer	0.000721	0.00284	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000718	0.00282	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000718	0.00282	CcSEcCtD
Nevirapine—Headache—Sorafenib—thyroid cancer	0.000717	0.00282	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000703	0.00276	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—thyroid cancer	0.000696	0.00274	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—thyroid cancer	0.000682	0.00268	CcSEcCtD
Nevirapine—Nausea—Sorafenib—thyroid cancer	0.00068	0.00267	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—thyroid cancer	0.000675	0.00265	CcSEcCtD
Nevirapine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000671	0.00264	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000658	0.00259	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—thyroid cancer	0.000652	0.00256	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000651	0.00256	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—thyroid cancer	0.000647	0.00254	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—thyroid cancer	0.000645	0.00254	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—thyroid cancer	0.000644	0.00253	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000628	0.00247	CcSEcCtD
Nevirapine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000621	0.00244	CcSEcCtD
Nevirapine—Agranulocytosis—Epirubicin—thyroid cancer	0.000619	0.00243	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000609	0.00239	CcSEcCtD
Nevirapine—Renal failure—Doxorubicin—thyroid cancer	0.000604	0.00237	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000602	0.00237	CcSEcCtD
Nevirapine—Jaundice—Doxorubicin—thyroid cancer	0.000599	0.00235	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—thyroid cancer	0.000597	0.00235	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—thyroid cancer	0.000596	0.00234	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000585	0.0023	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000581	0.00228	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—thyroid cancer	0.000573	0.00225	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—thyroid cancer	0.000563	0.00221	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—thyroid cancer	0.000551	0.00217	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000542	0.00213	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—thyroid cancer	0.000538	0.00211	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—thyroid cancer	0.000521	0.00205	CcSEcCtD
Nevirapine—Erythema—Epirubicin—thyroid cancer	0.000519	0.00204	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—thyroid cancer	0.000498	0.00196	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000481	0.00189	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—thyroid cancer	0.00048	0.00189	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—thyroid cancer	0.000479	0.00188	CcSEcCtD
Nevirapine—Malaise—Epirubicin—thyroid cancer	0.000468	0.00184	CcSEcCtD
Nevirapine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000445	0.00175	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—thyroid cancer	0.000444	0.00174	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—thyroid cancer	0.000442	0.00174	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—thyroid cancer	0.000442	0.00174	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000438	0.00172	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—thyroid cancer	0.000436	0.00171	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—thyroid cancer	0.000433	0.0017	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000423	0.00166	CcSEcCtD
Nevirapine—Oedema—Epirubicin—thyroid cancer	0.000423	0.00166	CcSEcCtD
Nevirapine—Nervous system disorder—Epirubicin—thyroid cancer	0.000415	0.00163	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000414	0.00163	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—thyroid cancer	0.000411	0.00162	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—thyroid cancer	0.000409	0.00161	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—thyroid cancer	0.000409	0.00161	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000406	0.00159	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—thyroid cancer	0.000404	0.00159	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—thyroid cancer	0.000403	0.00159	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—thyroid cancer	0.000392	0.00154	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000392	0.00154	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000386	0.00152	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000384	0.00151	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000383	0.00151	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—thyroid cancer	0.00038	0.0015	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—thyroid cancer	0.00038	0.00149	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—thyroid cancer	0.000376	0.00148	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—thyroid cancer	0.000373	0.00147	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—thyroid cancer	0.000368	0.00145	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000365	0.00144	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—thyroid cancer	0.000365	0.00143	CcSEcCtD
Nevirapine—Pain—Epirubicin—thyroid cancer	0.000362	0.00142	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000357	0.0014	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—thyroid cancer	0.000352	0.00138	CcSEcCtD
Nevirapine—Feeling abnormal—Epirubicin—thyroid cancer	0.000349	0.00137	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—thyroid cancer	0.000348	0.00137	CcSEcCtD
Nevirapine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000346	0.00136	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—thyroid cancer	0.00034	0.00134	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000338	0.00133	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—thyroid cancer	0.000338	0.00133	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—thyroid cancer	0.000336	0.00132	CcSEcCtD
Nevirapine—Pain—Doxorubicin—thyroid cancer	0.000335	0.00132	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—thyroid cancer	0.000335	0.00132	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—thyroid cancer	0.000335	0.00132	CcSEcCtD
Nevirapine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000323	0.00127	CcSEcCtD
Nevirapine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00032	0.00126	CcSEcCtD
Nevirapine—Hypersensitivity—Epirubicin—thyroid cancer	0.000312	0.00123	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—thyroid cancer	0.000311	0.00122	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—thyroid cancer	0.00031	0.00122	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—thyroid cancer	0.00031	0.00122	CcSEcCtD
Nevirapine—Asthenia—Epirubicin—thyroid cancer	0.000304	0.00119	CcSEcCtD
Nevirapine—Pruritus—Epirubicin—thyroid cancer	0.000299	0.00118	CcSEcCtD
Nevirapine—Diarrhoea—Epirubicin—thyroid cancer	0.00029	0.00114	CcSEcCtD
Nevirapine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000289	0.00113	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—thyroid cancer	0.000281	0.0011	CcSEcCtD
Nevirapine—Pruritus—Doxorubicin—thyroid cancer	0.000277	0.00109	CcSEcCtD
Nevirapine—Vomiting—Epirubicin—thyroid cancer	0.000269	0.00106	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—thyroid cancer	0.000268	0.00105	CcSEcCtD
Nevirapine—Rash—Epirubicin—thyroid cancer	0.000267	0.00105	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—thyroid cancer	0.000267	0.00105	CcSEcCtD
Nevirapine—Headache—Epirubicin—thyroid cancer	0.000265	0.00104	CcSEcCtD
Nevirapine—Nausea—Epirubicin—thyroid cancer	0.000251	0.000988	CcSEcCtD
Nevirapine—Vomiting—Doxorubicin—thyroid cancer	0.000249	0.000979	CcSEcCtD
Nevirapine—Rash—Doxorubicin—thyroid cancer	0.000247	0.00097	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—thyroid cancer	0.000247	0.00097	CcSEcCtD
Nevirapine—Headache—Doxorubicin—thyroid cancer	0.000245	0.000964	CcSEcCtD
Nevirapine—Nausea—Doxorubicin—thyroid cancer	0.000233	0.000914	CcSEcCtD
